<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03933956</url>
  </required_header>
  <id_info>
    <org_study_id>MEDiaN2018</org_study_id>
    <secondary_id>Duke-NUS-TIDR/2018/0010</secondary_id>
    <nct_id>NCT03933956</nct_id>
  </id_info>
  <brief_title>Metabolic Effects of the SGLT-2 Inhibitor Empagliflozin in Patients With Diabetic Nephropathy (MEDiaN)</brief_title>
  <acronym>(MEDiaN)</acronym>
  <official_title>Metabolic Effects of the SGLT-2 Inhibitor Empagliflozin in Patients With Diabetic Nephropathy (MEDiaN)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Singapore General Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Duke-NUS Graduate Medical School</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Singapore General Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The MEDiaN study aims to examine the state of fuel metabolism in participants with diabetic
      nephropathy (DN) before and after the use of the sodium-glucose transport protein 2 inhibitor
      (SGLT-2i) empagliflozin. The goals of the MEDiaN study are to better understand the
      contribution of fuel metabolism to the development of DN, and to determine if changes to fuel
      metabolism can have a positive impact on this disease.

      The MEDiaN study is a single-center single-arm open-label intervention study to examine the
      effects of empagliflozin 10mg daily taken for 30 days on fuel oxidation patterns in
      participants with type 2 diabetes and DN.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Diabetic nephropathy (DN) is a common cause of end-stage renal disease. MEDiaN study
      investigators hypothesize that dysregulated mitochondrial fuel oxidation is a major driver of
      diabetic nephropathy. The sodium-glucose transport protein 2 inhibitor (SGLT-2i)
      empagliflozin has been shown to slow the progression of DN in patients with diabetes.

      The MEDiaN study aims to examine the state of fuel metabolism in participants with DN before
      and after the use of the SGLT-2i empagliflozin. The goals of the MEDiaN study are to better
      understand the contribution of fuel metabolism to the development of DN, and to determine if
      changes to fuel metabolism can have a positive impact on this disease.

      The MEDiaN study is a single-center single-arm open-label intervention study to examine the
      effects of empagliflozin 10mg daily taken for 30 days on fuel oxidation patterns in
      participants with type 2 diabetes and DN.

      The MEDiaN study plans to recruit 40 participants aged 21 to 100 years of age with type 2
      diabetes mellitus and diabetic nephropathy. Participants will receive treatment with oral
      empagliflozin 10mg daily for 30 days. The state of fuel metabolism will be examined through
      metabolomics analysis of blood and urine samples before and after empagliflozin 10mg daily
      taken for 30 days.
    </textblock>
  </detailed_description>
  <overall_status>Suspended</overall_status>
  <why_stopped>
    The study will be temporarily suspended due to the COVID-19 situation.
  </why_stopped>
  <start_date type="Anticipated">May 2020</start_date>
  <completion_date type="Anticipated">August 31, 2020</completion_date>
  <primary_completion_date type="Anticipated">August 31, 2020</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <intervention_model_description>Single-arm open-label intervention study</intervention_model_description>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in lipid metabolome signature</measure>
    <time_frame>Baseline and after 30 days of treatment with empagliflozin 10mg daily</time_frame>
    <description>Change in lipid metabolome signature following 30 days of empagliflozin treatment</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in ketone signature</measure>
    <time_frame>Baseline and after 30 days of treatment with empagliflozin 10mg daily</time_frame>
    <description>Change in ketone signature following 30 days of empagliflozin treatment</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in amino acid metabolome signature</measure>
    <time_frame>Baseline and after 30 days of treatment with empagliflozin 10mg daily</time_frame>
    <description>Change in amino acid metabolome signature following 30 days of empagliflozin treatment</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">40</enrollment>
  <condition>Diabetic Nephropathies</condition>
  <arm_group>
    <arm_group_label>Empagliflozin-treated</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Oral empagliflozin tablets 10mg daily, taken for 30 days.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Empagliflozin 10 MG</intervention_name>
    <description>Oral empagliflozin 10mg daily for 30 days</description>
    <arm_group_label>Empagliflozin-treated</arm_group_label>
    <other_name>Jardiance</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion criteria:

          1. Man or woman between 21 and 100 years of age

          2. Type 2 diabetes mellitus as defined by:

               -  Fasting plasma glucose ≥7.0mmol/l, or

               -  Symptoms of hyperglycemia with casual plasma glucose ≥11.1 mmol/L, or

               -  2-hour plasma glucose ≥11.1 mmol/l after a 75-gram oral glucose load, or

               -  Known type 2 diabetes mellitus diagnosed by a medical practitioner

          3. Two or more measurements indicating increased urine protein excretion within 1-year

             Increased urine protein excretion is defined as:

               -  Urine microalbumin/creatinine ratio (ACR) &gt; 3.3 mg/mmol creatinine or

               -  Urine total protein/creatinine ratio (PCR) &gt; 0.2 g/urine creatinine

          4. Known diabetes duration &gt; 3 months

          5. HbA1c ≤9% (within 3 months prior to enrolment)

          6. Not currently treated with an SGLT-2 inhibitor, and have not received SGLT-2 inhibitor
             therapy within the last 10 weeks.

          7. Stable diabetes therapy for at least 3months as defined as:

               -  No increase in dose of diabetes medications by more than two-fold or

               -  No new agents added within the previous 3 months

          8. Stable doses of angiotensin converting enzyme (ACE) inhibitors or angiotensin
             AT(1)-receptor blockers (ARBs) for at least 3 months.

          9. Capable of providing informed consent

        Exclusion Criteria:

          1. Type 1 diabetes mellitus

          2. Ketosis-prone diabetes

          3. Previous diabetic ketoacidosis

          4. History of Fournier's gangrene or skin and soft tissue infections of the perineum

          5. Recurrent or severe urinary tract or genital mycotic infections, or history of
             genitourinary infection within 2 weeks prior to informed consent

          6. Significant renal impairment (estimated Glomerular Filtration Rate &lt; 45
             ml/min/1.73m2**)

          7. Dialysis or kidney transplant

          8. Renal artery stenosis

          9. Alanine aminotransferase or aspartate aminotransferase above 3x upper limit of normal

         10. Significant change in weight (≥10% in the preceding 6 months)

         11. Treatment with anti-obesity drugs

         12. Previous bariatric surgery or other gastrointestinal surgeries that induce chronic
             malabsorption

         13. Treatment with systemic glucocorticoids

         14. Blood dyscrasias or clinically significant anaemia (Haemoglobin &lt; 10 g/L)

         15. Medical condition likely to limit survival to less than 3 years

         16. Uncontrolled thyrotoxicosis, untreated hypothyroidism

         17. Any ongoing acute medical illnesses

         18. Hospitalization within 1 month prior to enrolment

         19. Nursing mothers

         20. Pregnancy, currently trying to become pregnant, or of child-bearing potential and not
             practicing an acceptable method of birth control or do not plan to continue using this
             method throughout the study

         21. Excessive alcohol intake (&gt; 1 unit per day for women and &gt; 2 units per day for men)

         22. History of drug abuse

         23. Pancreatic insulin deficiency from any cause (history of pancreatitis, pancreatic
             surgery)

         24. Known intolerance or allergic reactions to empagliflozin or other SGLT-2 inhibitors

         25. Current participation in another clinical trial, or ingestion of investigational drug
             in another trial within 30 days prior to enrolment.

         26. Presence of any non-DN renal glomerular disease (e.g. IgA nephropathy, lupus
             nephritis, membranous glomerulonephritis, focal segmental glomerular sclerosis)

         27. Any previous organ transplantation

         28. Any factors likely to limit adherence to interventions (e.g. dementia; alcohol or
             substance abuse; history of unreliability in medication taking or appointment keeping;
             significant concerns about participation in the study from spouse, significant other
             or family members)

         29. Failure to obtain informed consent from participant

         30. Presence of postural hypotension or clinically significant dehydration (reduced skin
             turgor, dry oral mucosa, hypotension)
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>21 Years</minimum_age>
    <maximum_age>100 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Yun Rui Amanda Lam, MBBS MRCP</last_name>
    <role>Principal Investigator</role>
    <affiliation>Singapore General Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Singapore General Hospital</name>
      <address>
        <city>Singapore</city>
        <zip>169608</zip>
        <country>Singapore</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Singapore</country>
  </location_countries>
  <reference>
    <citation>Liu JJ, Ghosh S, Kovalik JP, Ching J, Choi HW, Tavintharan S, Ong CN, Sum CF, Summers SA, Tai ES, Lim SC. Profiling of Plasma Metabolites Suggests Altered Mitochondrial Fuel Usage and Remodeling of Sphingolipid Metabolism in Individuals With Type 2 Diabetes and Kidney Disease. Kidney Int Rep. 2016 Dec 16;2(3):470-480. doi: 10.1016/j.ekir.2016.12.003. eCollection 2017 May.</citation>
    <PMID>29142974</PMID>
  </reference>
  <reference>
    <citation>Sharma K, Karl B, Mathew AV, Gangoiti JA, Wassel CL, Saito R, Pu M, Sharma S, You YH, Wang L, Diamond-Stanic M, Lindenmeyer MT, Forsblom C, Wu W, Ix JH, Ideker T, Kopp JB, Nigam SK, Cohen CD, Groop PH, Barshop BA, Natarajan L, Nyhan WL, Naviaux RK. Metabolomics reveals signature of mitochondrial dysfunction in diabetic kidney disease. J Am Soc Nephrol. 2013 Nov;24(11):1901-12. doi: 10.1681/ASN.2013020126. Epub 2013 Oct 10.</citation>
    <PMID>23949796</PMID>
  </reference>
  <reference>
    <citation>Vasilakou D, Karagiannis T, Athanasiadou E, Mainou M, Liakos A, Bekiari E, Sarigianni M, Matthews DR, Tsapas A. Sodium-glucose cotransporter 2 inhibitors for type 2 diabetes: a systematic review and meta-analysis. Ann Intern Med. 2013 Aug 20;159(4):262-74. doi: 10.7326/0003-4819-159-4-201308200-00007. Review.</citation>
    <PMID>24026259</PMID>
  </reference>
  <reference>
    <citation>Wanner C, Inzucchi SE, Lachin JM, Fitchett D, von Eynatten M, Mattheus M, Johansen OE, Woerle HJ, Broedl UC, Zinman B; EMPA-REG OUTCOME Investigators. Empagliflozin and Progression of Kidney Disease in Type 2 Diabetes. N Engl J Med. 2016 Jul 28;375(4):323-34. doi: 10.1056/NEJMoa1515920. Epub 2016 Jun 14.</citation>
    <PMID>27299675</PMID>
  </reference>
  <reference>
    <citation>Perrone-Filardi P, Avogaro A, Bonora E, Colivicchi F, Fioretto P, Maggioni AP, Sesti G, Ferrannini E. Mechanisms linking empagliflozin to cardiovascular and renal protection. Int J Cardiol. 2017 Aug 15;241:450-456. doi: 10.1016/j.ijcard.2017.03.089. Epub 2017 Mar 23. Review.</citation>
    <PMID>28395981</PMID>
  </reference>
  <reference>
    <citation>Mudaliar S, Alloju S, Henry RR. Can a Shift in Fuel Energetics Explain the Beneficial Cardiorenal Outcomes in the EMPA-REG OUTCOME Study? A Unifying Hypothesis. Diabetes Care. 2016 Jul;39(7):1115-22. doi: 10.2337/dc16-0542.</citation>
    <PMID>27289124</PMID>
  </reference>
  <reference>
    <citation>Ferrannini E, Muscelli E, Frascerra S, Baldi S, Mari A, Heise T, Broedl UC, Woerle HJ. Metabolic response to sodium-glucose cotransporter 2 inhibition in type 2 diabetic patients. J Clin Invest. 2014 Feb;124(2):499-508. doi: 10.1172/JCI72227. Epub 2014 Jan 27. Erratum in: J Clin Invest. 2014 Apr 1;124(4):1868.</citation>
    <PMID>24463454</PMID>
  </reference>
  <verification_date>May 2020</verification_date>
  <study_first_submitted>April 20, 2019</study_first_submitted>
  <study_first_submitted_qc>April 28, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">May 1, 2019</study_first_posted>
  <last_update_submitted>May 18, 2020</last_update_submitted>
  <last_update_submitted_qc>May 18, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">May 20, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Diabetic nephropathy</keyword>
  <keyword>Sodium-glucose Cotransporter 2 Inhibitors</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Kidney Diseases</mesh_term>
    <mesh_term>Diabetic Nephropathies</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Empagliflozin</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>No</document_has_sap>
      <document_date>December 9, 2018</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/56/NCT03933956/Prot_000.pdf</document_url>
    </provided_document>
  </provided_document_section>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

